GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

Part of paid clinical trials in Richmond, Virginia.

Sponsor
Virginia Commonwealth University
Study ID
NCT06636123
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Castration-resistant Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Investigational Agent Administration — DRUG
    GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity

Study Details

The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.

Key Dates

Start date
Feb 18, 2025
Status verified
Jan 2026
Primary completion
Apr 30, 2027
Completion
Oct 31, 2031

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Investigational Agent Administration
    GZ17-6.02: 375mg twice daily

Primary Outcome Measure

Radiologic progression-free survival (rPFS) for 6 months or longer [ Time Frame: 6 months and up to 5 years after end of study treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Virginia Commonwealth UniversityRichmondVirginia23298
Massey CTO GU Team
[email protected]
804-628-6430
John Melson, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Richmond, VA

By research site
Virginia Commonwealth University· Richmond, VA

Related Studies